The following discussion should be read in conjunction with the condensed consolidated financial statements and notes thereto appearing elsewhere in this Quarterly Report on Form 10-Q.

Except for the historical information contained herein, the matters discussed in this "Management's Discussion and Analysis of Financial Condition and Results of Operations," are forward-looking statements that involve risks and uncertainties. In some cases, these statements may be identified by terminology such as "may," "will," "should," "expects," "could," "intends," "might," "plans," "anticipates," "believes," "estimates," "predicts," "potential," or "continue," or the negative of such terms and other comparable terminology. These statements involve known and unknown risks and uncertainties that may cause our results, level of activity, performance or achievements to be materially different from those expressed or implied by the forward-looking statements. Factors that may cause or contribute to such differences include, among others, those discussed in Part I, Item 1A, Risk Factors, of our Annual Report on Form 10-K for the year ended December 31, 2007. Except as may be required by law, we undertake no obligation to update any forward-looking statement to reflect events after the date of this report.

Overview

We are a development stage medical device company focused on the design and development of devices that use neuroblocking technology to treat obesity and other gastrointestinal disorders. Our proprietary neuroblocking technology, which we refer to as VBLOC therapy, is designed to intermittently block the vagus nerve using high frequency, low energy, electrical impulses. We currently have no products approved for sale. Our initial product under development is the Maestro System, which uses VBLOC therapy to limit the expansion of the stomach, reduce the frequency and intensity of stomach contractions and produce a feeling of early and prolonged fullness. We were formerly known as Beta Medical, Inc. and were incorporated in Minnesota on December 19, 2002. We were reincorporated in Delaware on July 22, 2004. Since inception, we have devoted substantially all of our resources to the development and commercialization of our Maestro System.

Based on our understanding of vagal nerve function and nerve blocking from our preclinical studies and the results of our initial clinical trials, we believe the Maestro System may offer obese patients a minimally invasive treatment alternative that has the potential to result in significant and sustained weight loss. We believe that our Maestro System will allow bariatric surgeons to help obese patients who are concerned about the risks and complications associated with gastric banding and gastric bypass surgery. We are continuing to evaluate the Maestro System in human clinical trials conducted within the United States and internationally. Preliminary results from a feasibility study conducted outside the U.S., which includes 33 patients, indicates that the Maestro System may provide durable and ongoing weight-loss for people with obesity. Follow up data show excess weight loss, or EWL, of 29.1% in 12 patients at 12 months of VBLOC therapy, 27.4% in 17 patients at nine months of therapy and 21.4% in 28 patients at six months of therapy. We have completed enrollment and implantation of subjects in our first U.S. pivotal trial, the EMPOWER trial. We plan to review the data from our EMPOWER trial to support our premarket approval, or PMA, application in the middle of 2009 and submit the application for the Maestro System shortly thereafter. We anticipate commercialization in the United States beginning in 2010 if and when the FDA grants us approval. In addition, data from sub-group analyses demonstrate that VBLOC therapy may hold promise in improving the co-morbidities of diabetes and hypertension, independent of, and prior to, substantial weight loss. We are conducting, or plan to conduct, feasibility studies in each of these co-morbidities to assess VBLOC therapy's potential in addressing multiple indications.

If and when we obtain FDA approval of our Maestro System we intend to market our products in the United States through a direct sales force supported by field technical and marketing managers who provide training, technical and other support services to our customers. Outside the United States we intend to use direct, dealer or distributor sales models as the targeted geography best dictates. To date, we have relied on third-party manufacturers and suppliers for the production of our Maestro System. We currently anticipate that we will continue to rely on third-party manufacturers and suppliers for the production of the Maestro System following commercialization.

To date, we have generated no revenue from the sale of products, and we have incurred net losses in each year since our inception. As of September 30, 2008, we had a deficit accumulated during the development stage of $93.5 million. We expect our losses to continue and to increase as we continue our development activities and expand our commercialization activities. We have financed our operations primarily through public and private placement of our equity securities and issuance of debt.

Financial Overview

Revenue

To date, we have not commercialized any products and we have not generated any revenue. We do not expect to generate revenue until 2010 and then, only if we receive FDA approval of our Maestro System. Any revenue from initial sales of a new product is difficult to predict and in any event will only modestly reduce our continued and increasing losses resulting from our research and development and other activities.

Research and Development Expenses

Our research and development expenses primarily consist of engineering, product development and clinical and regulatory expenses, incurred in the development of our Maestro System. Research and development expenses also include employee compensation, including stock-based compensation, consulting services, outside services, materials, supplies, and travel. We expense research and development costs as they are incurred. From inception through September 30, 2008, we have incurred a total of $71.6 million in research and development expenses.

Selling, General and Administrative Expenses

Our selling, general and administrative expenses consist primarily of compensation for executive, finance, market development and administrative personnel, including stock-based compensation. Other significant expenses include costs associated with attending medical conferences, professional fees for legal services, including legal services associated with our efforts to obtain and maintain broad protection for the intellectual property related to our products, and accounting services, cash management fees, consulting fees and travel expenses. From inception through September 30, 2008, we have incurred $21.2 million in selling, general and administrative expenses.

Results of Operations

Comparison of the Three Months Ended September 30, 2008 and 2007

Research and Development Expenses. Research and development expenses were $8.2 million for the three months ended September 30, 2008, compared to $5.2 million for the three months ended September 30, 2007. The increase of $3.0 million, or 59.0%, is primarily due to increases of $390,000 and $3.2 million in compensation expense and professional services, respectively, to support the EMPOWER clinical study and completion of the Maestro RC System development efforts, offset by a decrease of $767,000 in device costs which were required in 2007 as the EMPOWER clinical study began ramping up. Employee stock-based compensation increased $92,000 due to new options granted since the third quarter of 2007. Nonemployee stock compensation charges decreased $166,000 due to a drop in the fair value of our common stock compared to the third quarter of 2007.

Selling, General and Administrative Expenses. Selling, general and administrative expenses were $1.9 million for the three months ended September 30, 2008, compared to $1.7 million for the three months ended September 30, 2007. The increase of $190,000, or 11.3%, is primarily due to increases of $323,000, $182,000 and $12,000 in employee stock-based compensation from new options granted since the third quarter of 2007, compensation expense due to increased headcount and professional services, respectively, offset by a decrease of $268,000 in nonemployee stock compensation charges due to a drop in the fair value of our common stock compared to the third quarter of 2007.

Interest Income. Interest income was $205,000 for the three months ended September 30, 2008, compared to $328,000 for the three months ended September 30, 2007. The decrease of $123,000, or 37.5%, is primarily due to a decrease in the short-term interest rate environment despite an increase in the average cash, cash equivalents and short-term investment balance from $24.3 million during the third quarter of 2007 to $31.9 million during the third quarter of 2008. The increased average cash, cash equivalents and short-term investments balance is the result of the net $39.1 million raised in our initial public offering in November 2007 and $10.0 million of debt funding received in 2007. We expect our quarterly interest income to continue decreasing in the future as we continue to use the proceeds of our initial public offering to fund our operations.

Interest Expense. Interest expense was $347,000 for the three months ended September 30, 2008, compared to $454,000 for the three months ended September 30, 2007. The decrease of $106,000, or 23.5%, was primarily due to the third quarter of 2007 including amortization expense of $132,000 for commitment warrants issued in conjunction with the $10.0 million debt agreement entered into on May 17, 2007.

Comparison of the Nine Months Ended September 30, 2008 and 2007

Research and Development Expenses. Research and development expenses were $23.3 million for the nine months ended September 30, 2008, compared to $13.9 million for the nine months ended September 30, 2007. The increase of $9.4 million, or 67.6%, is primarily due to increases of $1.2 million, $7.1 million and $159,000 in compensation expense, professional services and device costs, respectively, to support the EMPOWER clinical study and completion of the Maestro RC System development efforts. Employee stock based compensation increased $537,000 over the first nine months of 2007 due to new options granted during that period. Nonemployee stock compensation charges decreased $504,000 due to a drop in the fair value of our common stock and an increase in fully vested options compared to the first nine months of 2007.

Selling, General and Administrative Expenses. Selling, general and administrative expenses were $6.5 million for the nine months ended September 30, 2008, compared to $5.5 million for the nine months ended September 30, 2007. The increase of $1.1 million, or 19.3%, is primarily due to a $494,000 increase in professional services expense for public relations, investor relations and legal fees. Additionally, there was a $466,000 increase in compensation expense associated with increased headcount and a $151,000 increase associated with the cost of being a public company, including travel for attendance at investor conferences and meetings and

insurance. Employee stock based compensation increased $867,000 over the first nine months of 2007 due to new options granted. Nonemployee stock based compensation decreased $1.1 million due to a drop in the fair value of our common stock compared to the first nine months of 2007.

Interest Income. Interest income was $987,000 for the nine months ended September 30, 2008, compared to $1.1 million for the nine months ended September 30, 2007. The decrease of $103,000, or 9.4%, is primarily due to a decrease in the short-term interest rate environment despite an increase in the average cash, cash equivalents and short-term investment balance from $27.3 million during the nine months ended September 30, 2007 to $41.5 million during the nine months ended September 30, 2008. The increased average cash, cash equivalents and short-term investments balance is the result of the net $39.1 million raised in our initial public offering in November 2007 and $10.0 million of debt funding received in 2007. We expect our quarterly interest income to continue decreasing in the future as we continue to use the proceeds of our initial public offering to fund our operations.

Interest Expense. Interest expense was flat at $1.2 million for the nine months ended September 30, 2008 and for the nine months ended September 30, 2007. The slight decrease of $3,000, or 0.2%, was primarily due to $10.0 million of debt funding obtained throughout 2007 under the terms of a debt agreement entered into on May 17, 2007 offset by the amortization expense of $525,000 for commitment warrants issued in conjunction with the same debt agreement.

Change in Value of the Convertible Preferred Stock Warrant Liability. The change in value of the convertible preferred stock warrant liability was zero for the nine months ended September 30, 2008, compared to $362,000 for the nine months ended September 30, 2007. This is the result of a convertible preferred stock warrant liability being recorded on December 11, 2006 when we sold an additional 123,569 shares of Series C convertible preferred stock. Upon closing the sale, we had insufficient authorized and unissued shares of Series C convertible preferred stock available to share settle outstanding warrants to purchase Series C convertible preferred stock, resulting in the warrants being reclassified as a liability at the estimated fair value of $735,000 on December 11, 2006 and subsequently remeasured as of December 31, 2006 and March 31, 2007. The fair market value of the warrants as of March 31, 2007 and December 31, 2006 was $973,000 and $729,000, respectively. On May 14, 2007 we filed an amended certificate of incorporation to increase the number of authorized shares of Series C convertible preferred stock. As a result of the amendment, we had sufficient authorized and unissued shares of Series C convertible preferred stock available to share settle the warrants. The warrants were marked-to-market on May 14, 2007 and the convertible preferred stock liability was reclassified to additional paid-in capital. The fair market value of the warrants on May 14, 2007 was determined to be $1.1 million.

Liquidity and Capital Resources

We have incurred losses since our inception in December 2002 and, as of September 30, 2008 we had a deficit accumulated during the development stage of $93.5 million. We have financed our operations to date principally through sale of capital stock, debt financing and interest earned on investments. Prior to our initial public offering of stock in November 2007, we had received net proceeds of $63.2 million from the sale of common stock and preferred stock and $15.8 million in debt financing from a lender that provided $746,000 to finance equipment purchases and $15.0 million to finance working capital. Through our initial public offering we received net proceeds of $39.1 million after expenses and underwriters' discounts and commissions and including the exercise of the underwriters' over-allotment option.

As of September 30, 2008, we had $28.6 million in cash, cash equivalents and short-term investments. Of this amount $15.8 million was invested in short-term money market funds that are not considered to be bank deposits and are not insured or guaranteed by the federal deposit insurance company or other government agency. These money market funds seek to preserve the value of the investment at $1.00 per share; however, it is possible to lose money investing in these funds. Our cash and investment balances are held in a variety of interest bearing instruments, including obligations of U.S. government agencies, U.S. corporate bonds, commercial paper, asset-backed securities and money market funds. Cash in excess of immediate requirements is invested in accordance with our investment policy, primarily with a view to liquidity and capital preservation. At times, such deposits may be in excess of insured limits. We have not experienced any losses on our deposits of cash and cash equivalents.

The fair value of our short-term investment holdings are based on security prices from one or multiple industries established pricing sources. Examples of these pricing sources are Bloomberg, Interactive Data Corporation, Reuters, JJ Kenny, and Merrill Lynch. Each pricing source uses a different confidential method for pricing securities using various inputs, such as interest rates, known historical trades, yield curve information, benchmark data, prepayment speeds, credit quality, or broker/dealer quotes. Management regularly reviews the pricing methodology used by our third party asset managers to ensure consistency of the fair-value determination with SFAS 157 and proper classification of the underlying assets and liabilities within that standard's fair-value hierarchy. We also review each of our short-term investment positions and assess whether there is any other-than temporary impairment as well as the reasonableness of the fair market values being reported.

The remaining unpaid balance of the $7.6 million in debt financing is collateralized by a first security priority lien on all of our assets, excluding intellectual property. We have entered into account control agreements in order to perfect the lender's first security interest in our cash and investment accounts. In the event we have less than four remaining months of liquidity, we are required to grant a temporary lien on our intellectual property. The number of remaining months of liquidity is calculated by dividing cash and

cash equivalents as of the end of any particular month by the sum of our total operating expenses for each of the immediately preceding four months. There are no additional covenants that we are required to maintain under the terms of our debt financing agreements.

Net Cash Used in Operating Activities

Net cash used in operating activities was $24.2 million and $17.2 million for the nine months ended September 30, 2008 and 2007, respectively. Net cash used in operating activities primarily reflects the net loss for those periods, which was partially offset by depreciation and amortization, stock-based compensation and changes in operating assets and liabilities.

Net Cash Used in Investing Activities

Net cash used in investing activities was $935,000 for the nine months ended September 30, 2008 and is primarily related to purchases of short-term investments and, to a lesser extent, the purchase of property and equipment, partially offset by proceeds from the maturity of short-term investments. Net cash provided by investing activities was $10.0 million for the nine months ended September 30, 2007 and is primarily related to the proceeds from the maturity of short-term investments partially offset by the purchase of short-term investments and, to a lesser extent, the purchase of property and equipment.

Net Cash Used in Financing Activities

Net cash used in financing activities was $4.0 million for the nine months ended September 30, 2008 and is primarily attributable to the repayments of long-term debt. Net cash provided by financing activities was $5.6 million for the nine months ended September 30, 2007 and is primarily attributable to debt proceeds of $7.5 million partially offset by the repayments of long-term debt.

Operating Capital and Capital Expenditure Requirements

To date, we have not commercialized any products and we have not earned any operating revenues. We anticipate that we will continue to incur substantial net losses for the next several years as we develop our products, prepare for the potential commercial launch of our Maestro System, develop the corporate infrastructure required to sell our products and operate as a publicly-traded company as well as pursue additional applications for our technology platform.

We do not expect to generate significant product revenue until 2010. We do not anticipate generating any product revenue in the United States unless and until we successfully obtain FDA approval for our Maestro System. We believe the net proceeds from our initial public offering, together with our pre-existing cash, cash equivalents and short-term investment balances and interest income we earn on these balances will be sufficient to meet our anticipated cash requirements through the end of 2009. If our available cash, cash equivalents and investment balances are insufficient to satisfy our liquidity requirements, we may seek to sell additional equity or debt securities or enter into a credit facility agreement. The sale of additional equity and debt securities may result in dilution to our stockholders. If we raise additional funds through the issuance of debt securities, these securities could have rights senior to those of our common stock and could contain covenants that would restrict our operations. We may require additional capital beyond our currently forecasted amounts. Any such required additional capital may not be available on reasonable terms, if at all. If we are unable to obtain additional financing, we may be required to reduce the scope of, delay, or eliminate some or all of, our planned research, development and commercialization activities, which could materially harm our business.

Our forecast of the period of time through which our financial resources will be adequate to support our operations, the costs to complete development of products and the cost to commercialize our products are forward-looking statements and involve risks and uncertainties, and actual results could vary materially and negatively as a result of a number of factors, including the factors discussed in Part I, Item 1A, Risk Factors, of our Annual Report on Form 10-K for the year ended December 31, 2007. We have based these estimates on assumptions that may prove to be wrong, and we could utilize our available capital resources sooner than we currently expect.

Because of the numerous risks and uncertainties associated with the development of medical devices, such as our Maestro System, we are unable to estimate the exact amounts of capital outlays and operating expenditures necessary to complete the development of the products and successfully deliver a commercial product to the market. Our future capital requirements will depend on many factors, including but not limited to the following:

• the scope, rate of progress, results and cost of our clinical trials and other research and development activities;

• the cost and timing of regulatory approvals;

• the cost and timing of establishing sales, marketing and distribution capabilities;

• the cost of establishing clinical and commercial supplies of our Maestro System and any products that we may develop;

• the rate of market acceptance of our Maestro System and VBLOC therapy and any other product candidates;

• the cost of filing and prosecuting patent applications and defending and enforcing our patent and other intellectual property rights;

• the effect of competing products and market developments;

• the cost of explanting clinical devices;

• the terms and timing of any collaborative, licensing or other arrangements that we may establish;

• any revenue generated by sales of our future products; and

• the extent to which we acquire or invest in businesses, products and technologies, although we currently have no commitments or agreements relating to any of these types of transactions.

Critical Accounting Policies and Estimates

We prepare our consolidated financial statements in accordance with accounting principles generally accepted in the United States. In doing so, we have to make estimates and assumptions that affect our reported amounts of assets, liabilities and expenses, as well as related disclosure of contingent assets and liabilities. In many cases, we could reasonably have used different accounting policies and estimates. In some cases, changes in the accounting estimates are reasonably likely to occur from period to period. Accordingly, actual results could differ materially from our estimates. To the extent that there are material differences between these estimates and actual results, our financial condition or results of operations will be affected. We base our estimates on past experiences and other assumptions that we believe are reasonable under the circumstances, and we evaluate these estimates on an ongoing basis.

Our significant accounting policies are fully described in Note 2 to our consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2007 filed with the SEC.

Contractual Obligations

During the nine months ended September 30, 2008, there were no material changes to our contractual obligation disclosures as set forth under the caption, "Contractual Obligations" in Part II, Item 7, Management's Discussion and Analysis of Financial Condition and Results of Operations, of our Annual Report on Form 10-K for the year ended December 31, 2007, other than those described below.

Effective October 1, 2008 the Company entered into a seven-year non-cancelable operating lease agreement for office/warehouse space. The leased space will continue to include furnished office space and various research and development labs. The lease expires on September 30, 2015 with monthly base rent ranging from $19,570 to $24,643.

The following table summarizes our contractual obligations as of September 30, 2008 and the effect those obligations are expected to have on our financial condition and liquidity position in future periods:

                                                             Payments Due By Period
                                                       Less Than                               More than
Contractual Obligations                   Total         1 Year       1-3 Years    3-5 Years     5 Years
Operating lease                        $  1,896,106   $   234,839   $   512,733   $  562,896   $  585,638
Long-term debt                            8,492,263     4,609,313     3,882,950           -            -
Other long-term liabilities                 350,000       300,000        50,000           -            -

Total contractual cash obligations     $ 10,738,369   $ 5,144,152   $ 4,445,683   $  562,896   $  585,638

The table above reflects only payment obligations that are fixed and determinable. Our operating lease commitments relate to our corporate headquarters in St. Paul, Minnesota. Other long-term liabilities consist of obligations required under the terms of our license agreement with the Mayo Foundation for Medical Education and Research, or Mayo Foundation.

Off-Balance Sheet Arrangements

As of September 30, 2008, we did not have any off-balance sheet arrangements.

Recent Accounting Pronouncements

In September 2006, FASB issued Statement of Financial Accounting Standards No. 157 (SFAS 157), Fair Value Measurements, which defines fair value, establishes guidelines for measuring fair value and expands disclosures regarding fair value measurements. SFAS 157 does not require any new fair value measurements but rather eliminates inconsistencies in guidance found in various . . .